Drug Profile
AZD 9898
Alternative Names: AZD9898Latest Information Update: 12 Feb 2018
Price :
$50
*
At a glance
- Originator Orexo
- Developer AstraZeneca
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Leukotriene-C4 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 12 Feb 2018 Discontinued - Phase-I for Asthma in United Kingdom (PO) (AstraZeneca pipeline, February 2018)
- 17 Jan 2018 AstraZeneca terminates a phase I trial in Asthma in United Kingdom after an interim review (NCT03140072)
- 13 Sep 2017 Pharmacodynamic results from preclinical studies in Asthma presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)